Cholangiocarcinoma: a retrospective analysis of our experience in diagnosis, prognostic factors, staging and treatment

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter E. Inga
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors E. Inga1, G. Padilla Maria2, M. Gonzalez3, E. Casaut2, A. González-Haba1, J. Gomez-Ulla2
  • 1Hospital Universitario Infanta Cristina, Badajoz, Spain, /
  • 2Hospital Infanta Cristina, Badajoz, Spain, /
  • 3Resident of Oncology, Badajoz, Spain, /


Cholangiocarcinoma (CCA) is a relatively uncommon malignant tumor arising in the intrahepatic and extrahepatic biliary ducts. It accounts for about 3% of all gastrointestinal cancers globally. CCA is classified as intrahepatic, perihilar or distal extrahepatic; the individual subtypes differ in their biologic behavior, clinical presentation, and management. The incidence and mortality of CCA has been increasing over the past 3 decades, and only a low percentage of patients survive until 5 years after diagnosis. There is an urgent requirement for effective diagnosis and treatment strategies against this devastating disease. The purpose of this study is to review our experience with the diagnosis, staging and treatment of the different stages in a series of patients with cholangiocarcinoma.